



WHAT IS CLAIMED IS:


1. A compound of the structural formula I



- 5 or a pharmaceutically acceptable salt thereof; wherein
 X is O or S;
 Z is O or S;
 R¹ is hydrogen, methyl, C₁₋₁₆ alkylcarbonyl, C₂₋₁₈ alkenylcarbonyl, C₁₋₁₀ alkyloxycarbonyl,
 C₃₋₆ cycloalkylcarbonyl, C₃₋₆ cycloalkyloxycarbonyl, CH₂O(C=O)C₁₋₄ alkyl, CH(C₁₋₄
 10 alkyl)O(C=O)C₁₋₄ alkyl, or an amino acyl residue of structural formula



- R² is hydrogen, hydroxy, fluoro, amino, methyl, methoxy, C₁₋₁₆ alkylcarbonyloxy, C₂₋₁₈
 alkenylcarbonyloxy, C₁₋₁₀ alkyloxycarbonyloxy, C₃₋₆ cycloalkylcarbonyloxy,
 C₃₋₆ cycloalkyloxycarbonyloxy, -OCH₂O(C=O)C₁₋₄ alkyl, -OCH(C₁₋₄ alkyl)O(C=O)C₁₋₄
 15 alkyl, or an amino acyloxy residue of structural formula



R³ is selected from the group consisting of methyl, ethynyl, cyano, aminocarbonyl, fluoromethyl, bromomethyl, trifluoromethyl, aminomethyl, fluoro, chloro, and bromo;


R⁴ is hydrogen, C₁₋₁₀ alkylcarbonyl, C₂₋₁₈ alkenylcarbonyl, C₁₋₁₀ alkyloxycarbonyl, C₃₋₆ cycloalkylcarbonyl, C₃₋₆ cycloalkyloxycarbonyl, CH₂O(C=O)C₁₋₄ alkyl, CH(C₁₋₄ alkyl)O(C=O)C₁₋₄ alkyl, P₃O₉H₄, P₂O₆H₃, P(O)R⁷R⁸, or an amino acyl residue of structural formula



R⁵ is hydrogen, C₁₋₄ alkyl, or phenyl C₀₋₂ alkyl;

R⁶ is hydrogen, C₁₋₄ alkyl, C₁₋₄ acyl, benzoyl, C₁₋₄ alkyloxycarbonyl, phenyl C₀₋₂ alkyloxycarbonyl, C₁₋₄ alkylaminocarbonyl, phenyl C₀₋₂ alkylaminocarbonyl, C₁₋₄ alkylsulfonyl, or phenyl C₀₋₂ alkylsulfonyl; and

10 R⁷ and R⁸ are each independently hydroxy, OCH₂CH₂SC(=O)C₁₋₄ alkyl, OCH₂O(C=O)OC₁₋₄ alkyl, NHCHMeCO₂Me, OCH(C₁₋₄ alkyl)O(C=O)C₁₋₄ alkyl,



with the proviso that when X and Z are O, R¹ and R⁴ are hydrogen, and R² is hydroxy, then R³ is not methyl, fluoromethyl, ethynyl, or cyano.

15


2. The compound of Claim 1 wherein X and Z are O.

3. The compound of Claim 1 wherein

R¹ is hydrogen, C₁₋₁₆ alkylcarbonyl, or an aminoacyl residue of structural formula




R² is hydroxy, C₁₋₁₆ alkylcarbonyloxy, or an amino acyloxy residue of structural formula



R³ is methyl or fluoromethyl; and

R⁴ is hydrogen, C₁₋₁₀ alkylcarbonyl, P₃O₉H₄, or an amino acyl residue of structural formula




- 5 with the proviso that when X and Z are O, R¹ and R⁴ are hydrogen, and R² is hydroxy, then R³ is not methyl, fluoromethyl, ethynyl, or cyano.

4. A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

5. The pharmaceutical composition of Claim 4 useful for inhibiting RNA-dependent RNA viral polymerase, inhibiting RNA-dependent RNA replication, and/or treating RNA-dependent RNA viral infection.

6. The pharmaceutical composition of Claim 5 wherein said RNA-dependent RNA viral polymerase is HCV NS5B polymerase, said RNA-dependent RNA viral replication is HCV replication, and said RNA-dependent RNA viral infection is HCV infection.

7. A method of treating RNA-dependent RNA viral infection comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of structural formula I:




or a pharmaceutically acceptable salt thereof; wherein


X is O or S;

Z is O or S;


- 5 R^1 is hydrogen, methyl, C₁₋₁₆ alkylcarbonyl, C₂₋₁₈ alkenylcarbonyl, C₁₋₁₀ alkyloxycarbonyl, C₃₋₆ cycloalkylcarbonyl, C₃₋₆ cycloalkyloxycarbonyl, CH₂O(C=O)C₁₋₄ alkyl, CH(C₁₋₄ alkyl)O(C=O)C₁₋₄ alkyl, or an amino acyl residue of structural formula



- 10 R^2 is hydrogen, hydroxy, fluoro, amino, methyl, methoxy, C₂₋₁₈ alkenylcarbonyloxy, C₂₋₁₈ alkenylcarbonyloxy, C₁₋₁₀ alkyloxycarbonyloxy, C₃₋₆ cycloalkylcarbonyloxy, C₃₋₆ cycloalkyloxycarbonyloxy, -OCH₂O(C=O)C₁₋₄ alkyl, -OCH(C₁₋₄ alkyl)O(C=O)C₁₋₄ alkyl, or an amino acyloxy residue of structural formula




- 15 R^3 is selected from the group consisting of methyl, ethynyl, cyano, aminocarbonyl, fluoromethyl, bromomethyl, trifluoromethyl, aminomethyl, fluoro, chloro, and bromo;
 R^4 is hydrogen, C₁₋₁₀ alkylcarbonyl, C₂₋₁₈ alkenylcarbonyl, C₁₋₁₀ alkyloxycarbonyl, C₃₋₆ cycloalkylcarbonyl, C₃₋₆ cycloalkyloxycarbonyl, CH₂O(C=O)C₁₋₄ alkyl, CH(C₁₋₄ alkyl)O(C=O)C₁₋₄ alkyl, P₃O₉H₄, P₂O₆H₃, P(O)R⁷R⁸, or an amino acyl residue of structural formula



R⁵ is hydrogen, C₁₋₄ alkyl, or phenyl C₀₋₂ alkyl;

R⁶ is hydrogen, C₁₋₄ alkyl, C₁₋₄ acyl, benzoyl, C₁₋₄ alkyloxycarbonyl, phenyl C₀₋₂ alkyloxycarbonyl, C₁₋₄ alkylaminocarbonyl, phenyl C₀₋₂ alkylaminocarbonyl, C₁₋₄ alkylsulfonyl, or phenyl C₀₋₂ alkylsulfonyl; and


R⁷ and R⁸ are each independently hydroxy, OCH₂CH₂SC(=O)C₁₋₄ alkyl, OCH₂O(C=O)OC₁₋₄ alkyl, NHCHMeCO₂Me, OCH(C₁₋₄ alkyl)O(C=O)C₁₋₄ alkyl,




8. The method of Claim 7 wherein X and Z are O.

9. The method of Claim 8 wherein

R¹ is hydrogen, C₁₋₁₆ alkylcarbonyl, or an aminoacyl residue of structural formula




R² is hydroxy, C₁₋₁₆ alkylcarbonyloxy, or an amino acyloxy residue of structural formula



R³ is methyl or fluoromethyl; and

R⁴ is hydrogen, C₁₋₁₀ alkylcarbonyl, P₃O₉H₄, or an amino acyl residue of structural formula



10. The method of Claim 9 wherein the compound of formula I is 4'-C-methylcytidine or 4'-C-(fluoromethyl)cytidine; or a pharmaceutically acceptable salt thereof.

5 11. The method of Claim 7 wherein said RNA-dependent RNA viral infection is HCV infection.

12. The method of Claim 11 in combination with a therapeutically effective amount of another agent active against HCV.

10 13. The method of Claim 12 wherein said agent active against HCV is ribavirin; levovirin; thymosin alpha-1; interferon- β ; an inhibitor of NS3 serine protease; an inhibitor of inosine monophosphate dehydrogenase; interferon- α or pegylated interferon- α , alone or in combination with ribavirin or levovirin.

15 14. The method of Claim 13 wherein said agent active against HCV is interferon- α or pegylated interferon- α , alone or in combination with ribavirin.

20 15. A method of treating HCV infection in a mammal in need thereof comprising administering to such mammal a therapeutically effective amount of 4'-C-methylcytidine or a pharmaceutically acceptable salt thereof.